BRIEF-Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC Filing

Reuters03-07

March 6 (Reuters) - Incyte Corp INCY.O:

INCYTE - FDA ISSUES COMPLETE RESPONSE LETTER FOR ZYNYZ SBLA IN NSCLC - SEC FILING
INCYTE - CRL CITES CATALENT INDIANA REGULATORY COMPLIANCE AS SOLE APPROVABILITY ISSUE - SEC FILING

Further company coverage: INCY.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617653151?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-07 06:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617653151","market":"us","top_or_hot":-1,"title":"BRIEF-Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC Filing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC Filing</title></head><body><p><span>March 6 (Reuters)</span><span> - </span>Incyte Corp <span>INCY.O</span>:</p><ul><li><p>INCYTE - FDA ISSUES COMPLETE RESPONSE LETTER FOR ZYNYZ SBLA IN NSCLC - SEC FILING</p></li><li><p>INCYTE - CRL CITES CATALENT INDIANA REGULATORY COMPLIANCE AS SOLE APPROVABILITY ISSUE - SEC FILING</p></li></ul><p>Further company coverage: <span>INCY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-07 06:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC Filing</title></head><body><p><span>March 6 (Reuters)</span><span> - </span>Incyte Corp <span>INCY.O</span>:</p><ul><li><p>INCYTE - FDA ISSUES COMPLETE RESPONSE LETTER FOR ZYNYZ SBLA IN NSCLC - SEC FILING</p></li><li><p>INCYTE - CRL CITES CATALENT INDIANA REGULATORY COMPLIANCE AS SOLE APPROVABILITY ISSUE - SEC FILING</p></li></ul><p>Further company coverage: <span>INCY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nFWN3ZU1GX:1","article_id":"2617653151","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617653151","pubTimestamp":1772834866,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC FilingMarch 6  - Incyte Corp INCY.O:INCYTE - FDA ISSUES COMPLETE RESPONSE LETTER FOR ZYNYZ SBLA IN NSCLC - SEC FILINGINCYTE - CRL CITES CATALENT INDIANA REGULATORY COMPLIANCE AS SOLE APPROVABILITY ISSUE - SEC FILINGFurther company coverage: INCY.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4588":"碎股","INCY":"因塞特医疗","BK4585":"ETF&股票定投概念","BK4550":"红杉资本持仓"},"translate_title":"简介-Incyte-FDA在NSCLC-SEC备案中发布Zynyz Sbla的完整回复信","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"BRIEF-Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC FilingMarch 6 (Reuters) - Incyte Corp INCY.O:INCYTE - FDA ISSUES COMPLETE RESPONSE LETTER FOR ZYNYZ SBLA IN NSCLC - SEC FILINGINCYTE - CRL CITES CATALENT INDIANA REGULATORY COMPLIANCE AS SOLE APPROVABILITY ISSUE - SEC FILINGFurther company coverage: INCY.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617653151","isCrawlerRequest":true}